Australia

The Therapeutic Goods Administration (TGA) is the primary national regulatory authority responsible for evaluating, registering, and monitoring all therapeutic goods in Australia, including prescription and over-the-counter medicines, medical devices, in vitro diagnostics (IVDs), biologicals, and digital health products where they meet the definition of a therapeutic device. The governing legislative framework is the Therapeutic Goods Act 1989, supported by the Therapeutic Goods Regulations 1990 and a suite of subordinate instruments and orders. Products must generally be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully supplied in Australia. Approval pathways vary by product class: pharmaceuticals may follow standard, priority, or provisional registration routes; medical devices are classified using a risk-based scheme (Class I through Class III, including IVD classes) with conformity assessment requirements; and biologicals follow a separate tiered framework. The TGA also administers the Special Access Scheme (SAS) and the Authorised Prescriber scheme for unapproved products.

Sponsor eligibility requires that all therapeutic goods have an Australian sponsor: a legal entity with a registered business address in Australia that assumes regulatory responsibility for the product. Overseas manufacturers must hold a valid TGA manufacturing licence or demonstrate compliance with an acceptable overseas regulatory authority under a mutual recognition arrangement. Australia accepts the Common Technical Document (CTD) format for pharmaceutical submissions and aligns device conformity assessments with internationally recognised standards, including ISO 13485 and IEC 62304 for software. The TGA participates in the Access Consortium (formerly MSIA) with Canada, Singapore, Switzerland, and the United Kingdom, enabling parallel scientific review and work-sharing for medicines and devices. Recent reforms include the introduction of the International Recognition Procedure (IRP), launched in 2023, which allows sponsors to leverage prior approvals from comparable overseas regulators (such as the US FDA, EMA, Health Canada, MHRA, or Swissmedic) to streamline Australian registration. The TGA has also progressively updated its regulatory framework for software as a medical device (SaMD) and personalised medicine, and has strengthened post-market surveillance obligations and incident reporting requirements for sponsors and manufacturers.

Australia operates a federated health system in which both the Commonwealth (federal) government and eight state and territory governments share responsibility for health funding and service delivery. At the federal level, the Commonwealth funds the Pharmaceutical Benefits Scheme (PBS), administered by the Department of Health and Aged Care, which subsidises listed medicines for the Australian population. PBS listing requires a separate health technology assessment (HTA) process conducted by the Pharmaceutical Benefits Advisory Committee (PBAC), which evaluates comparative clinical effectiveness and cost-effectiveness before recommending reimbursement. For medical devices and diagnostics, the Prostheses List (PL) governs benefits payable by private health insurers for devices implanted in hospital, while the Medicare Benefits Schedule (MBS) covers eligible procedures and certain diagnostic tests in both public and private settings. State and territory governments independently procure medicines, devices, and health technologies for their public hospital systems through state health departments and hospital networks, often using state-based formularies, tender processes, and procurement agencies such as HealthShare NSW, System Information and Analytics (Victoria), and the State Procurement Board (South Australia). National coordination is facilitated through bodies such as the Australian Commission on Safety and Quality in Health Care (ACSQHC) and the Medical Services Advisory Committee (MSAC), which advises on MBS listings for new medical services and technologies.

The private sector plays a substantial role in Australian healthcare, with approximately half the population holding private hospital insurance. Private hospitals, pathology providers, and specialist practices procure health products through a mix of direct commercial contracts, group purchasing organisations (GPOs), and distributor agreements, with pricing largely negotiated bilaterally rather than through centralised tender. Australia is a high-income country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi; these mechanisms are therefore not applicable to the domestic market. However, Australia is an active donor and contributor to global health procurement initiatives through the Department of Foreign Affairs and Trade (DFAT) and its development assistance programs in the Indo-Pacific region. Local manufacturing preference policies have gained increased policy attention following supply chain disruptions during the COVID-19 pandemic: the Commonwealth has invested in sovereign manufacturing capability through initiatives such as the Medical and Scientific Industrial Strategy and partnerships with onshore vaccine and medicine manufacturers, and procurement guidelines increasingly consider supply chain resilience and domestic production capacity as evaluation criteria alongside price and quality.